Jacob Johnson
Stock Analyst at Stephens & Co.
(2.84)
# 1,594
Out of 5,129 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $243.47 | -1.43% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.58 | -8.75% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.23 | -17.01% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $30.47 | +96.94% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $219.98 | +43.19% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $527.17 | +28.99% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $139.40 | +21.95% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $2.11 | +136.97% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $0.73 | +1,406.44% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $15.60 | +143.59% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $8.50 | +100.00% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.15 | +16.28% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $63.45 | +37.12% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $246.16 | +58.43% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $11.45 | +57.21% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.19 | +404.20% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $22.25 | +30.34% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $185.96 | -30.09% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $165.98 | +127.14% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $243.47
Upside: -1.43%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.58
Upside: -8.75%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.23
Upside: -17.01%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $30.47
Upside: +96.94%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $219.98
Upside: +43.19%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $527.17
Upside: +28.99%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $139.40
Upside: +21.95%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $2.11
Upside: +136.97%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.73
Upside: +1,406.44%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $15.60
Upside: +143.59%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $8.50
Upside: +100.00%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.15
Upside: +16.28%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $63.45
Upside: +37.12%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $246.16
Upside: +58.43%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $11.45
Upside: +57.21%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.19
Upside: +404.20%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $22.25
Upside: +30.34%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $185.96
Upside: -30.09%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $165.98
Upside: +127.14%